Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) finished Friday with an addition of $0.69 to close at $25.45, an upside of 2.79 percent. An average of 655,300 shares of common stock have been traded in the last five days. There was a gain of $0.23 in the past week, and it reached a new high 6 times over the past 12 months. The last 20 days have seen an average of 1,157,795 shares traded, while the 50-day average volume stands at 878,016.
SNDX stock has increased by 6.22% in the last month. The company shares reached their 1-month lowest point of $20.25 on 12/09/22. With the stock rallying to its 52-week high on 10/06/22, shares of the company touched a low of $13.27 and a high of $26.51 in 52 weeks. It has reached a new high 6 times so far this year and achieved 16.26% or $3.56 in price. In spite of this, the price is down -4.00% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
SNDX stock investors should be aware that Syndax Pharmaceuticals Inc. (SNDX) stock had its last reported insider trading activity 29 days ago on Dec 02. In this transaction, the insider spent $430,936. Chief Scientific Officer, Ordentlich Peter, disposed of 7,800 shares at a price of $25.01 on Dec 01. The insider now owns more than $195,089 worth of shares. Prior to that, Director Katkin Keith went on to Sale 29,899 shares at $25.90 each on Oct 06. An amount of $774,411 was transacted.
Syndax Pharmaceuticals Inc. (SNDX) stock’s beta is 1.09. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 14.21, the price-to-book (PB) ratio at 4.57.
The quick ratio of Syndax Pharmaceuticals Inc. for the three months ended June 29 was 17.20, and the current ratio was 17.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $113.49 million compared to revenue of $139.71 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Syndax Pharmaceuticals Inc.’s return on assets was -3.40%.
For the three-month period that ended June 29, Syndax Pharmaceuticals Inc. had $279.33 million in cash. The company posted a net income of -$35.4 million in the quarter, while revenues of -$37.57 million were grew 41.69%. The analyst consensus anticipated Syndax Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.64 per share, but it turned out to be -$0.62, a 3.10% surprise. For the quarter, EBITDA amounted to -$36.17 million. Shareholders own equity worth $60.22 million.
From a technical analysis perspective, let’s take a brief look at Syndax Pharmaceuticals Inc. (SNDX) price momentum. RSI 9-day as of the close on 30 December was 61.75%, suggesting the stock is Neutral, with historical volatility in this time frame at 53.19%.
As of today, SNDX’s price is $24.31 +0.91% or $0.23 from its 5-day moving average. SNDX is currently trading +1.68% higher than its 20-day SMA and +6.09% higher than its 100-day SMA. However, the stock’s current price level is +15.31% above the SMA50 and +49.09% above the SMA200.
The stochastic %K and %D were 81.64% and 72.83%, respectively, and the average true range (ATR) was 1.29. With the 14-day stochastic at 97.25% and the average true range at 1.31, the RSI (14) stands at 58.71%. The stock has reached 0.35 on the 9-day MACD Oscillator while the 14-day reading was at 0.31.
The consensus rating for Syndax Pharmaceuticals Inc. (SNDX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SNDX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 6 others rate it as a “buy”.
What is SNDX’s price target for the next 12 months?
Analysts predict a range of price targets between $29.00 and $39.00, with a median target of $33.00. Taking a look at these predictions, the average price target given by analysts for Syndax Pharmaceuticals Inc. (SNDX) stock is $33.14.